Another report demonstrated that although IL-10 therapy improves various inflammatory parameters and liver fibrosis in patients with chronic HCV infection, in the long term it may lead to increased HCV burden via alterations in immunologic viral surveillance (64). The gene discussed is IL10; the disease is Hepatic fibrosis.